Endobetix
Minimally Invasive Solution for Type 2 Diabetes and Obesity
Company Overview
Snapshot
Founded in August 2012 by Chen Porat, Endobetix operates with 1–10 employees. The company has raised $650,000 across one funding round from one investor. In July 2015, Endobetix was awarded a U.S. patent, marking a significant intellectual property milestone.
Business overview
Endobetix is developing a minimally invasive, nonsurgical implant designed to treat Type 2 Diabetes and obesity. Its core technology, the Endobetix Bile Diversion Device (BDD), is implanted endoscopically to reroute bile and pancreatic secretions, altering hormonal balance to improve glucose tolerance and reduce fat absorption. This device serves the healthcare industry, specifically targeting gastroenterologists and bariatric surgeons for outpatient procedures, and operates within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment.
Strategic signal
In July 2015, Endobetix secured a U.S. patent for its technology. This intellectual property validation is a critical signal to investors, demonstrating the novelty and defensibility of the company's minimally invasive solution for Type 2 Diabetes and obesity within the competitive medical device landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Endobetix's primary focus?
- Endobetix focuses on developing a minimally invasive, non-surgical implant for the treatment of Type 2 Diabetes and obesity.
- When was Endobetix founded?
- Endobetix was founded in August 2012.
- What is the Endobetix Bile Diversion Device (BDD)?
- The BDD is an endoscopically implanted device that reroutes bile and pancreatic secretions to improve glucose tolerance and reduce fat absorption by changing hormonal balance.
- What significant intellectual property milestone did Endobetix achieve?
- In July 2015, Endobetix was awarded a U.S. patent for its technology, providing strong validation of its innovative approach to treating Type 2 Diabetes and obesity.
- Which award was Endobetix a finalist for in 2015?
- In April 2015, Endobetix was a finalist for the Red Herring Top 100 Europe Award.